Executive Summary
Revvity delivered a profitable Q1 2025, but topline momentum cooled against prior year and the prior quarter. Revenue totaled $664.76 million, down 2.82% year-over-year and 8.86% quarter-over-quarter, while gross margin remained robust at 49.2% (gross profit $327.25 million). The company generated $128.16 million of cash from operations and reported free cash flow of $112.17 million, supporting a strong liquidity position as of March 30, 2025. Net income was $41.44 million with an EPS of $0.345, reflecting disciplined cost management in an environment of revenue headwinds. EBITDA stood at $172.77 million with an EBITDA margin of about 26.0%, underscoring earnings quality despite top-line declines.
Key Performance Indicators
QoQ: -9.02% | YoY:-14.96%
QoQ: -33.50% | YoY:-14.26%
QoQ: -56.40% | YoY:-55.90%
QoQ: -55.78% | YoY:-54.92%
Key Insights
Revenue: $664.762 million; YoY change: -2.82%; QoQ change: -8.86%.
Gross Profit: $327.246 million; Gross margin: 49.22%; YoY: -14.96%; QoQ: -9.02%.
Operating Income: $87.971 million; Operating margin: 13.23%; YoY: -14.26%; QoQ: -33.50%.
Net Income: $41.437 million; Net margin: 6.23%; YoY: -55.90%; QoQ: -56.40%.
EPS: $0.3449; Diluted EPS: $0.3446; YoY: -54.92%; QoQ: -55.78%.
EBITDA: $172.768 million; EBITDA margin: 25.99% (EBITDA relative to revenue).
Cash flow: Operating cash flow $128.155 milli...
Financial Highlights
Revenue: $664.762 million; YoY change: -2.82%; QoQ change: -8.86%.
Gross Profit: $327.246 million; Gross margin: 49.22%; YoY: -14.96%; QoQ: -9.02%.
Operating Income: $87.971 million; Operating margin: 13.23%; YoY: -14.26%; QoQ: -33.50%.
Net Income: $41.437 million; Net margin: 6.23%; YoY: -55.90%; QoQ: -56.40%.
EPS: $0.3449; Diluted EPS: $0.3446; YoY: -54.92%; QoQ: -55.78%.
EBITDA: $172.768 million; EBITDA margin: 25.99% (EBITDA relative to revenue).
Cash flow: Operating cash flow $128.155 million; Free cash flow $112.173 million.
Balance sheet highlights: Cash and cash equivalents $1.13762 billion; Total assets $12.3607 billion; Total liabilities $4.7236 billion; Total stockholders’ equity $7.6371 billion; Net debt $2.1877 billion; Current ratio 3.58; Quick ratio 2.99; Debt ratio 0.269; Debt/Equity 0.435.
Capital allocation: Share repurchases of $153.594 million; Dividends paid $8.433 million; Net cash used by financing activities $(163.664) million.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
664.76M |
-2.82% |
-8.86% |
| Gross Profit |
327.25M |
-14.96% |
-9.02% |
| Operating Income |
87.97M |
-14.26% |
-33.50% |
| Net Income |
41.44M |
-55.90% |
-56.40% |
| EPS |
0.34 |
-54.92% |
-55.78% |
Key Financial Ratios
operatingProfitMargin
13.2%
operatingCashFlowPerShare
$1.07
freeCashFlowPerShare
$0.93
dividendPayoutRatio
20.4%
Management Commentary
Note: The earnings transcript was not provided in the dataset. As a result, no verbatim management quotes or call-by-call thematic highlights could be extracted. The analysis below references the disclosed P&L, cash flow, and balance sheet metrics and contextual industry considerations. If a transcript becomes available, we can integrate management tone on growth initiatives, pipeline progress, and non-GAAP metrics.
Forward Guidance
Explicit management forward guidance for QQ2/2025 or full-year 2025 was not included in the provided data. Given the Q1 2025 results, near-term drivers to monitor include: (1) trajectory of the Diagnostics and Discovery/Analytical Solutions segments and any resulting pricing/purchase momentum; (2) trajectory of R&D investment versus cost discipline contributing to maintaining EBITDA/margin stability; (3) working capital dynamics and capital expenditure cadence that influence free cash flow generation; (4) potential M&A activity or strategic partnerships that could alter the growth trajectory. Our assessment: in a base case with continued demand stabilization and cost discipline, Revvity can sustain EBITDA margins in the mid-20s and maintain robust free cash flow, supporting additional deleveraging or opportunistic buybacks if cash flow remains strong. Key factors investors should monitor include backlog signals, order activity in genomics and genomic workflows, and any updated non-GAAP earnings metrics or segment guidance from management.